<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Hematol Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Hematol Oncol</journal-id>
      <journal-title-group>
        <journal-title>Journal of Hematology &amp; Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-8722</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27012666</article-id>
      <article-id pub-id-type="pmc">4806434</article-id>
      <article-id pub-id-type="publisher-id">259</article-id>
      <article-id pub-id-type="doi">10.1186/s13045-016-0259-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Kuo-Hsing</given-names>
          </name>
          <address>
            <email>jeff40537@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff4"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yuan</surname>
            <given-names>Chang-Tsu</given-names>
          </name>
          <address>
            <email>cyclonoel@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tseng</surname>
            <given-names>Li-Hui</given-names>
          </name>
          <address>
            <email>lhtseng@ntu.edu.tw</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shun</surname>
            <given-names>Chia-Tung</given-names>
          </name>
          <address>
            <email>ctshun@ntu.edu.tw</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff7"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Yeh</surname>
            <given-names>Kun-Huei</given-names>
          </name>
          <address>
            <phone>+886 2 23123456</phone>
            <email>khyeh@ntu.edu.tw</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Oncology, National Taiwan University Hospital, 7, Chun-Shan S Rd, Taipei, 10002 Taiwan </aff>
        <aff id="Aff2"><label/>Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan </aff>
        <aff id="Aff3"><label/>Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan </aff>
        <aff id="Aff4"><label/>National Taiwan University Cancer Center, Taipei, Taiwan </aff>
        <aff id="Aff5"><label/>Department of Forensic Medicine, National Taiwan University, Taipei, Taiwan </aff>
        <aff id="Aff6"><label/>Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan </aff>
        <aff id="Aff7"><label/>Forensic Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>9</volume>
      <elocation-id>29</elocation-id>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>2</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Chen et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Anti-programmed death-1 therapy has poor efficacy in mismatch repair-proficient (pMMR) colorectal cancers; however, its efficacy in pMMR gastric cancers remains undetermined. Here, we report the case of a patient with pMMR and microsatellite-stable gastric cancer who exhibited a partial response to salvage anti-programmed death-1 therapy with pembrolizumab.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>Initially, the patient underwent subtotal gastrectomy 4&#xA0;years ago for early-stage gastric cancer (pT1bN2M0, stage IIA). Immunohistochemical analysis of the tumor revealed strongly positive for HER2/neu. He had received trastuzumab plus pertuzumab, cisplatin, and capecitabine for recurrent tumors since September 2014 for 15 cycles. Disease progression of gastric cancer was found in August 2015. Since September 2015, the patient has received pembrolizumab monotherapy (200&#xA0;mg as a fixed dose, every 3&#xA0;weeks) for 3&#xA0;months and the repeat computed tomography demonstrated a confirmed partial response. The plasma carcinoembryonic antigen also decreased dramatically. Both immunohistochemistry and a polymerase chain reaction-based method revealed that the patient had pMMR gastric cancer.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This case report provides the first report that mismatch repair-proficient and microsatellite-stable gastric cancers can respond well to anti-PD-1 monotherapy and indicates both markers may not sufficiently be predictive of anti-PD-1 therapy resistance in gastric cancer.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Gastric cancer</kwd>
        <kwd>Immunotherapy</kwd>
        <kwd>Anti-programmed death-1 antibody</kwd>
        <kwd>Mismatch repair deficiency</kwd>
        <kwd>Mismatch repair proficiency</kwd>
        <kwd>Microsatellite stability</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>Center of Excellence for Cancer Research (2014 to 2017), National Taiwan University Hospital</institution>
          </funding-source>
          <award-id>MOHW105-TDU-B-211-134004</award-id>
          <principal-award-recipient>
            <name>
              <surname>Yeh</surname>
              <given-names>Kun-Huei</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Immune checkpoint blockade therapies such as those using anti-cytotoxic T lymphocyte-associated protein 4 antibodies and those blocking programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have exhibited promising efficacy in several types of cancer [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR7">7</xref>]. Moreover, the heterogeneous response to immune checkpoint blockade therapy observed in patients in these studies has raised the importance of identifying predictive biomarkers. Mutation or hypermethylation in mismatch repair genes (<italic>MLH1</italic>, <italic>MSH2</italic>, <italic>MSH6</italic>, or <italic>PMS2</italic>) leads to deficient mismatch repair (dMMR) and causes accumulation errors in DNA sequences, thus increasing the risk of colorectal cancer (CRC) and other epithelial cancers [<xref ref-type="bibr" rid="CR8">8</xref>]. Recently, Le et al. reported that patients with mismatch repair-deficient CRC and those with mismatch repair-deficient noncolorectal cancer exhibited higher response rates to PD-1 blockade monotherapy (pembrolizumab). In addition, they suggested that hypermutated tumor-associated neoantigens from dMMR are the primary factors affecting the response to anti-PD-1 therapy; previous studies have observed that this therapy stimulated the endogenous immune response [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. However, Le et al. also reported that none of 18 patients with mismatch repair-proficient (pMMR) CRC responded to pembrolizumab, an anti-PD-1 antibody. The efficacy of PD-1 blockade therapy in pMMR noncolorectal cancers and a biomarker for PD-1 blockade remain unknown. Here, we report the case of a 64-year-old man with pMMR and microsatellite-stable (MSS) gastric cancer who exhibited a partial response to salvage pembrolizumab monotherapy.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 64-year-old man experienced epigastralgia with tarry stool in late 2011. Esophagogastroduodenoscopy revealed a circular ulcer in the prepyloric area. Biopsy was performed, and the pathology of the specimen revealed gastric adenocarcinoma. On the basis of computed tomography (CT), the gastric cancer was clinically staged as cT3N0M0, stage IIA. He underwent radical subtotal gastrectomy, Billroth II anastomosis, D2 dissection, and cholecystectomy on December 28, 2011. The pathology of the specimen revealed a well-differentiated adenocarcinoma, and <italic>Helicobacter pylori</italic> infection was not observed (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>). Immunohistochemically, tumor cells were strongly positive (3+, according to the proposal by Hofmann et al. [<xref ref-type="bibr" rid="CR11">11</xref>]) for HER2/neu immunostain (clone 4B5, 1:2 dilution; Fig&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). The pathological staging of the gastric cancer was pT1bN2M0, stage IIA. After surgery, he was followed up regularly at our hospital without adjuvant treatment.<fig id="Fig1"><label>Fig. 1</label><caption><p>Histopathology of the gastric cancer and its HER2 immunohistochemistry. Microscopic observation revealed a well-differentiated adenocarcinoma with frequent luminal formation and evident nuclear atypia infiltration within a mild desmoplastic stroma; H &amp; E stain (<bold>a</bold>). In the metastasized lymph node, the tumor cells were strongly positive for the HER2/neu immunostain (<italic>brown color</italic>) (<bold>b</bold>); original magnification &#xD7;100</p></caption><graphic xlink:href="13045_2016_259_Fig1_HTML" id="MO1"/></fig></p>
      <p>Two years later, CT and positron emission tomography revealed tumor recurrence in the left lower paratracheal lymph nodes. The patient was then enrolled in a clinical trial and received 15 cycles of pertuzumab (840&#xA0;mg on D1, every 3&#xA0;weeks) in combination with trastuzumab (562&#xA0;mg on D1, every 3&#xA0;weeks) and chemotherapy (80&#xA0;mg/m<sup>2</sup> cisplatin on D1 and 1000&#xA0;mg/m<sup>2</sup> capecitabine twice a day on D1&#x2013;D14, every 3&#xA0;weeks). He was dropped from the study in August 2015 because the tumors (peritoneal seeding and paraaortic lymph nodes) progressed and his plasma carcinoembryonic antigen (CEA) level increased from 4.78 to 348&#xA0;ng/mL. The best response of the treatment was stable disease with a first-line progression-free survival of 11&#xA0;months.</p>
      <p>In September 2015, the patient started receiving pembrolizumab (200&#xA0;mg as a fixed dose, every 3&#xA0;weeks) as a second-line treatment for recurrent gastric cancer. No adverse event was observed in the following 2&#x2013;3&#xA0;months. Two months later, CT revealed tumor regression and a partial response was confirmed in another CT scan 1&#xA0;month later (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). In addition, the plasma CEA level decreased from 607.1 to 26.96&#xA0;ng/mL. To investigate the association of the tumor factors with the efficacy of PD-1 blockade as well as to confirm whether he had pMMR gastric cancer, we used both immunohistochemistry (IHC) and a polymerase chain reaction-based method (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR12">12</xref>]. In addition, we performed IHC analyses of previous specimens from gastrectomy, which revealed few tumor-infiltrating lymphocytes (TILs) in tumors and invasive fronts, as demonstrated by the presence of CD3 (polyclonal, 1:100), CD4 (clone MT310, 1:50), and CD8 (clone DK-25, 1:200; Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4a&#x2013;c</xref>). Epstein&#x2013;Barr virus (EBV)-encoded small RNA (EBER) in situ hybridization revealed absence of EBV in the tumor cells (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4d</xref>). The tumor cells were also negative for PD-L1 (B7H1, Abcam, clone ab58810, 1:400; Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>) [<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, no polymerase epsilon (<italic>POLE</italic>) mutation was found by means of Sanger sequencing of exon 9. As of January 2016, the patient was still continuing the pembrolizumab monotherapy with excellent performance status and quality of life.<fig id="Fig2"><label>Fig. 2</label><caption><p>Computed tomography scan of the recurrent tumors before and after pembrolizumab treatment</p></caption><graphic xlink:href="13045_2016_259_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Immunohistochemistry of MMR protein. The tumor cells preserved expression of MLH1 (<bold>a</bold>), MSH2 (<bold>b</bold>), PMS2 (<bold>c</bold>), and MSH6 (<bold>d</bold>); original magnification &#xD7;400</p></caption><graphic xlink:href="13045_2016_259_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Tumor-infiltrating lymphocytes and EBV status. The invasive front is highlighted by a <italic>yellow dashed line</italic>, which separates the tumor part (<italic>T</italic>) from the nontumor part (<italic>NT</italic>). Few CD3(+) tumor-infiltrating lymphocytes (<italic>brown spot</italic>) (<bold>a</bold>). The infiltrating CD3(+) cells were composed mainly of CD4(+) cells (<italic>brown spot</italic>) (<bold>b</bold>) and a few CD8(+) cells (<italic>brown spot</italic>) (<bold>c</bold>). The invasive front had only a few lymphocytes. Most of the lymphocytes were scattered between tumor nests rather than within tumor nests. EBER in situ hybridization revealed no evidence of EBV infection in the tumor cells (positive is denoted by a dark blue spot in nuclei) (<bold>d</bold>); original magnification: &#xD7;100</p></caption><graphic xlink:href="13045_2016_259_Fig4_HTML" id="MO4"/></fig><fig id="Fig5"><label>Fig. 5</label><caption><p>Immunohistochemistry of PD-L1 protein. The tumor cells were negative for PD-L1 (B7-H1); original magnification &#xD7;400</p></caption><graphic xlink:href="13045_2016_259_Fig5_HTML" id="MO5"/></fig></p>
      <sec id="Sec3">
        <title>Discussion</title>
        <p>Evaluations of the efficacy of PD-1 blockade in advanced esophagogastric junction (EGJ) and gastric adenocarcinoma are still preliminary, and an accurate predictive biomarker remains to be determined. Bang et al. reported that the overall response rate of pembrolizumab (by central review) in advanced PD-L1-positive gastric cancer was 22.2&#xA0;% [95&#xA0;% confidence interval, 10.1&#x2013;39.2] in a phase I study (KEYNOTE-012 study, gastric cancer cohort) [<xref ref-type="bibr" rid="CR14">14</xref>]. Of the 162 patients screened, 65 were positive for PD-L1. The PD-L1 expression was detected through a prototype IHC assay by using the 223C antibody, and the tumors were determined positive for PD-L1 when PD-L1 staining was observed in the stroma or &#x2265;1&#xA0;% of tumor nest cells. However, PD-L1 expression is not yet a validated predictive biomarker for PD-1 blockade in gastric cancer. Moreover, dMMR has been identified in gastric cancer in several studies with the incidence ranging from 9 to 22&#xA0;% [<xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR19">19</xref>]. In a study conducted using the Cancer Genome Atlas (TCGA), 22&#xA0;% of the tumors belonged to the microsatellite instability (MSI) subtype, with the features of hypermutation and <italic>MLH1</italic> silencing. Although pMMR has been shown to predict poor efficacy of PD-1 blockade in CRC, the association of pMMR and PD-1 blockade in EGJ and gastric adenocarcinoma remains unknown. This case report provides the first report that pMMR and MSS gastric cancers can respond well to anti-PD-1 monotherapy. However, larger studies are warranted to explore the association between mismatch repair status and the efficacy of anti-PD-1 therapy in advanced gastric cancer.</p>
        <p>The hypothesis that neoantigens from hypermutated tumors may enhance the response of immune checkpoint therapy was supported by clinical correlative studies on melanoma and non-small-cell lung cancer [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In addition to dMMR, inactivating <italic>POLE</italic> mutation, found in CRC, endometrial cancer, and gastric cancer, can result in an extremely high mutation burden [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Howitt et al. demonstrated that increased TILs in the tumor microenvironment in <italic>POLE</italic>-mutated endometrial cancers make these tumors satisfactory candidates for immune checkpoint therapy [<xref ref-type="bibr" rid="CR23">23</xref>]. We cannot completely exclude the possibility that our patient had a <italic>POLE</italic>-mutated tumor; however, the incidence of <italic>POLE</italic> mutation in gastric cancer is very low (0.47&#xA0;%) and TILs in the tumor microenvironment were scant in our patient [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
        <p>PD-L1 has been reported to be overexpressed in EBV-associated malignancies, such as EBV-associated lymphoproliferative diseases, nasopharyngeal carcinoma, and HHV8-associated primary effusion lymphoma [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The mechanisms underlying increased PD-L1 expression in Hodgkin lymphoma include genetic amplification of <italic>CD274</italic> (encoding PD-L1) and constitutive AP1 signaling. The TCGA study also revealed that the amplification of <italic>CD274</italic> and <italic>PDCD1LG2</italic> (also encoding PD-L1 and PD-L2) was enhanced in the EBV-positive gastric cancer subgroup [<xref ref-type="bibr" rid="CR15">15</xref>]. Thus, these cancers are attractive targets for immune checkpoint therapy. In our patient, EBER in situ hybridization revealed absence of EBV in the tumor cells, and it is unlikely that the efficacy of anti-PD-1 therapy is affected by EBV-related <italic>CD274</italic> and <italic>PDCD1LG2</italic> amplification.</p>
      </sec>
    </sec>
    <sec id="Sec4">
      <title>Conclusions</title>
      <p>In conclusion, we report the case of a patient with pMMR and MSS gastric cancer who exhibited a confirmed objective response to PD-1 blockade, pembrolizumab monotherapy. Our case report indicates that mismatch repair proficiency and microsatellite stability may not be predictive to resistance of anti-PD-1 therapy, and factors other than dMMR and EBV infection may contribute to the response to anti-PD-1 therapy.</p>
      <sec id="Sec5">
        <title>Consent for publication</title>
        <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. The institutional review board of National Taiwan University Hospital approved the study.</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CRC</term>
          <def>
            <p>colorectal cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p>computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>dMMR</term>
          <def>
            <p>deficient mismatch repair</p>
          </def>
        </def-item>
        <def-item>
          <term>EBV</term>
          <def>
            <p>Epstein&#x2013;Barr virus</p>
          </def>
        </def-item>
        <def-item>
          <term>EBER</term>
          <def>
            <p>Epstein&#x2013;Barr virus-encoded small RNA</p>
          </def>
        </def-item>
        <def-item>
          <term>EGJ</term>
          <def>
            <p>esophagogastric junction</p>
          </def>
        </def-item>
        <def-item>
          <term>IHC</term>
          <def>
            <p>immunohistochemistry</p>
          </def>
        </def-item>
        <def-item>
          <term>PD-1</term>
          <def>
            <p>programmed death-1</p>
          </def>
        </def-item>
        <def-item>
          <term>PD-L1</term>
          <def>
            <p>programmed death ligand-1</p>
          </def>
        </def-item>
        <def-item>
          <term>pMMR</term>
          <def>
            <p>mismatch repair-proficient</p>
          </def>
        </def-item>
        <def-item>
          <term>MSI</term>
          <def>
            <p>microsatellite instability</p>
          </def>
        </def-item>
        <def-item>
          <term>MSS</term>
          <def>
            <p>microsatellite stable</p>
          </def>
        </def-item>
        <def-item>
          <term>POLE</term>
          <def>
            <p>polymerase epsilon</p>
          </def>
        </def-item>
        <def-item>
          <term>TCGA</term>
          <def>
            <p>the Cancer Genome Atlas</p>
          </def>
        </def-item>
        <def-item>
          <term>TILs</term>
          <def>
            <p>tumor-infiltrating lymphocytes</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>Dr. Yeh had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. KH Yeh and KH Chen did the study concept, design, and drafting of the manuscript. KH Yeh, KH Chen, CT Shun, and CT Yuan did the acquisition, analysis, and interpretation of data. LH Tseng did the genetic testing of microsatellite instability and <italic>POLE</italic> mutations. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <sec id="FPar1">
        <title>Funding</title>
        <p>This study was supported by a grant from Center of Excellence for Cancer Research (2014 to 2017), National Taiwan University Hospital (MOHW105-TDU-B-211-134004).</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hodi</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>O&#x2019;Day</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>McDermott</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Sosman</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Haanen</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schadendorf</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hassel</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>363</volume>
          <issue>8</issue>
          <fpage>711</fpage>
          <lpage>723</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1003466</pub-id>
          <pub-id pub-id-type="pmid">20525992</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Topalian</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Hodi</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Brahmer</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Gettinger</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>McDermott</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Powderly</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Carvajal</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Sosman</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Atkins</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>366</volume>
          <issue>26</issue>
          <fpage>2443</fpage>
          <lpage>2454</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1200690</pub-id>
          <pub-id pub-id-type="pmid">22658127</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Le</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Uram</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bartlett</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Kemberling</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Eyring</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Skora</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Luber</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Azad</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Laheru</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>PD-1 blockade in tumors with mismatch-repair deficiency</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>372</volume>
          <issue>26</issue>
          <fpage>2509</fpage>
          <lpage>2520</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id>
          <pub-id pub-id-type="pmid">26028255</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ansell</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lesokhin</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Borrello</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Halwani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Gutierrez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schuster</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Millenson</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Cattry</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&#x2019;s lymphoma</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>372</volume>
          <issue>4</issue>
          <fpage>311</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1411087</pub-id>
          <pub-id pub-id-type="pmid">25482239</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brahmer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Reckamp</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Baas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Crino</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Eberhardt</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Poddubskaya</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Antonia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pluzanski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vokes</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Holgado</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>373</volume>
          <issue>2</issue>
          <fpage>123</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1504627</pub-id>
          <pub-id pub-id-type="pmid">26028407</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larkin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chiarion-Sileni</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Grob</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Cowey</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Lao</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Schadendorf</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dummer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Smylie</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rutkowski</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Combined nivolumab and ipilimumab or monotherapy in untreated melanoma</article-title>
          <source>N Engl J Med</source>
          <year>2015</year>
          <volume>373</volume>
          <issue>1</issue>
          <fpage>23</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1504030</pub-id>
          <pub-id pub-id-type="pmid">26027431</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brahmer</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Tykodi</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>LQ</given-names>
            </name>
            <name>
              <surname>Hwu</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Topalian</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Hwu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Drake</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Camacho</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Kauh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Odunsi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Safety and activity of anti-PD-L1 antibody in patients with advanced cancer</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>366</volume>
          <issue>26</issue>
          <fpage>2455</fpage>
          <lpage>2465</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1200694</pub-id>
          <pub-id pub-id-type="pmid">22658128</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lynch</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>de la Chapelle</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Hereditary colorectal cancer</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>348</volume>
          <issue>10</issue>
          <fpage>919</fpage>
          <lpage>932</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra012242</pub-id>
          <pub-id pub-id-type="pmid">12621137</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Llosa</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Cruise</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wicks</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Hechenbleikner</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Taube</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Blosser</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Luber</surname>
              <given-names>BS</given-names>
            </name>
          </person-group>
          <article-title>The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints</article-title>
          <source>Cancer discovery</source>
          <year>2015</year>
          <volume>5</volume>
          <issue>1</issue>
          <fpage>43</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0863</pub-id>
          <pub-id pub-id-type="pmid">25358689</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vogelstein</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences</article-title>
          <source>Am J Pathol</source>
          <year>1994</year>
          <volume>145</volume>
          <issue>1</issue>
          <fpage>148</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="pmid">8030745</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hofmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stoss</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Gaiser</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kneitz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Heinmoller</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gutjahr</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Henkel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ruschoff</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy</article-title>
          <source>Journal of clinical pathology</source>
          <year>2008</year>
          <volume>61</volume>
          <issue>1</issue>
          <fpage>89</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.1136/jcp.2006.043562</pub-id>
          <pub-id pub-id-type="pmid">17412870</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>LI</given-names>
            </name>
            <name>
              <surname>Tseng</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Liau</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Jeng</surname>
              <given-names>YM</given-names>
            </name>
          </person-group>
          <article-title>Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma</article-title>
          <source>Modern pathology</source>
          <year>2015</year>
          <volume>28</volume>
          <issue>2</issue>
          <fpage>268</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1038/modpathol.2014.96</pub-id>
          <pub-id pub-id-type="pmid">25081749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shi</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Wen</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <issue>10</issue>
          <fpage>e76012</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0076012</pub-id>
          <pub-id pub-id-type="pmid">24124529</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">Bang YJ, Shankaran V, Geva R, Yang AG, Wen WH. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol. 2015;33(suppl; abstr 4001).</mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Cancer Genome Atlas Research N</collab>
          </person-group>
          <article-title>Comprehensive molecular characterization of gastric adenocarcinoma</article-title>
          <source>Nature</source>
          <year>2014</year>
          <volume>513</volume>
          <issue>7517</issue>
          <fpage>202</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="doi">10.1038/nature13480</pub-id>
          <pub-id pub-id-type="pmid">25079317</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Loss of ARID1A expression in gastric cancer: correlation with mismatch repair deficiency and clinicopathologic features</article-title>
          <source>Journal of gastric cancer</source>
          <year>2015</year>
          <volume>15</volume>
          <issue>3</issue>
          <fpage>201</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="doi">10.5230/jgc.2015.15.3.201</pub-id>
          <pub-id pub-id-type="pmid">26468418</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Grieken</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Aoyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Bottomley</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Inam</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Buffart</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Pang</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study</article-title>
          <source>Br J Cancer</source>
          <year>2013</year>
          <volume>108</volume>
          <issue>7</issue>
          <fpage>1495</fpage>
          <lpage>1501</lpage>
          <pub-id pub-id-type="doi">10.1038/bjc.2013.109</pub-id>
          <pub-id pub-id-type="pmid">23511561</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Shun</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Sheu</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes</article-title>
          <source>Genes Chromosomes Cancer</source>
          <year>2000</year>
          <volume>27</volume>
          <issue>4</issue>
          <fpage>403</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1098-2264(200004)27:4&lt;403::AID-GCC10&gt;3.0.CO;2-1</pub-id>
          <pub-id pub-id-type="pmid">10719371</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simpson</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Caballero</surname>
              <given-names>OL</given-names>
            </name>
            <name>
              <surname>Pena</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>Microsatellite instability as a tool for the classification of gastric cancer</article-title>
          <source>Trends Mol Med</source>
          <year>2001</year>
          <volume>7</volume>
          <issue>2</issue>
          <fpage>76</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1016/S1471-4914(01)01916-5</pub-id>
          <pub-id pub-id-type="pmid">11286759</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Snyder</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Makarov</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Merghoub</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zaretsky</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Desrichard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Postow</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>TS</given-names>
            </name>
          </person-group>
          <article-title>Genetic basis for clinical response to CTLA-4 blockade in melanoma</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>371</volume>
          <issue>23</issue>
          <fpage>2189</fpage>
          <lpage>2199</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1406498</pub-id>
          <pub-id pub-id-type="pmid">25409260</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rizvi</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Hellmann</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Snyder</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kvistborg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Makarov</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Havel</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>TS</given-names>
            </name>
          </person-group>
          <article-title>Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer</article-title>
          <source>Science (New York, NY)</source>
          <year>2015</year>
          <volume>348</volume>
          <issue>6230</issue>
          <fpage>124</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="doi">10.1126/science.aaa1348</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Palles</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cazier</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Howarth</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Domingo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Broderick</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kemp</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Spain</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Guarino</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Salguero</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas</article-title>
          <source>Nat Genet</source>
          <year>2013</year>
          <volume>45</volume>
          <issue>2</issue>
          <fpage>136</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.2503</pub-id>
          <pub-id pub-id-type="pmid">23263490</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Howitt</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Shukla</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Sholl</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Ritterhouse</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Watkins</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Rodig</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stover</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Strickland</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>D&#x2019;Andrea</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1</article-title>
          <source>JAMA oncology</source>
          <year>2015</year>
          <volume>1</volume>
          <issue>9</issue>
          <fpage>1319</fpage>
          <lpage>1323</lpage>
          <pub-id pub-id-type="doi">10.1001/jamaoncol.2015.2151</pub-id>
          <pub-id pub-id-type="pmid">26181000</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Chapuy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ouyang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Roemer</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Shipp</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies</article-title>
          <source>Clinical cancer research</source>
          <year>2013</year>
          <volume>19</volume>
          <issue>13</issue>
          <fpage>3462</fpage>
          <lpage>3473</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0855</pub-id>
          <pub-id pub-id-type="pmid">23674495</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Rodig</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Juszczynski</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ouyang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sinha</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>O&#x2019;Donnell</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Neuberg</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Shipp</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy</article-title>
          <source>Clinical cancer research</source>
          <year>2012</year>
          <volume>18</volume>
          <issue>6</issue>
          <fpage>1611</fpage>
          <lpage>1618</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1942</pub-id>
          <pub-id pub-id-type="pmid">22271878</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
